AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

Pfizer and Triana Biomedicines have entered into a strategic collaboration and licensing agreement worth over $1.5bn to discover molecular glue degraders (MGDs) for cancer and other severe diseases.

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) has been recommended by the National Institute of Health and Care Excellence (NICE) to treat resectable non-small cell ...

AstraZeneca’s (AZ) Voydeya (danicopan) has been recommended by the National Institute for Health and Care Excellence (NICE) as an add-on therapy for adults with the rare blood disorder paroxysmal ...

Pharma struggles to differentiate the experiences it provides, missing opportunities to achieve desirable business results and help HCPs at their point of need When a restaurant surprises you by ...

The health technology assessment agency said that more evidence is needed on the clinical and cost-effectiveness of the drug Eli Lilly’s amyloid plaque-targeting Alzheimer’s disease (AD) drug has been ...

Novo Nordisk’s Alhemo (concizumab) has been recommended by the European Medicines Agency’s human medicines committee to prevent bleeding in haemophilia patients aged 12 years or older. If approved, ...

The pharmaceutical industry is undergoing a transformative shift, recognising the critical importance of diversity in clinical trials. Ensuring that research findings are applicable and beneficial to ...

The healthcare communications industry is in ‘re-set’ mode. Challenges with resourcing and budgets mean in-house and agency teams must work harder and more collaboratively than ever to demonstrate ...

Influencer marketing has emerged as one of the most pervasive and persuasive media approaches in today’s landscape. As of 2024, there are over 50 million social media influencers active worldwide, ...

Next Wednesday, Rachel Reeves will deliver Labour’s first Budget in 15 years. As anticipation mounts on what will be included – and not included – I’ve taken some time to consider what measures are ...

You’ve come so far – painstaking R&D, promising phase 2 results and endless hours in the lab. But here’s the harsh truth – the hardest hurdle is still to come. Most products fall when it matters most ...